|
Hematologic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
JAK2 fusion genes are rare but recurrent abnormalities associated with diverse, clinically heterogeneous hematologic malignancies.
|
22875628 |
2013 |
|
Hematologic Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Although multiple mutations within JAK2, which abrogate the function of JH2 and sustain JAK2 activation, are widely observed in hematological malignancies, comparable mutations have not been detected in solid tumors.
|
23676499 |
2013 |
|
Hematologic Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Myeloproliferative neoplasms (MPN) are clonal hematological malignancies that are frequently -associated with an acquired somatic mutation in JAK2 (JAK2V617F).
|
21761323 |
2011 |
|
Hematologic Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The gain of function mutation JAK2-V617F is very frequently found in myeloproliferative neoplasms (MPNs) and is strongly implicated in pathogenesis of these and other hematological malignancies.
|
24404189 |
2014 |
|
Hematologic Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
The Janus kinase 2 (JAK2)-signal transducers and activators of transcription (STAT) pathway plays an important role in hematological malignancies.
|
19136931 |
2009 |
|
Hematologic Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We also discuss the role of JAK inhibitors for treatment of CSF3RT618I-mutated chronic neutrophilic leukemia and hematologic malignancies with rearranged JAK2 gene.
|
25520049 |
2014 |
|
Hematologic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
|
23926298 |
2013 |
|
Hematologic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
The human JAK2 gene is mainly targeted by two types of genetic lesions that play roles in the pathogenesis of hematologic malignancies: intragenic mutations and chromosomal translocations.
|
25833723 |
2015 |
|
Hematologic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Ruxolitinib is an oral JAK1 and JAK2 inhibitor that has recently been approved for the treatment of myelofibrosis and has been tested against other hematologic malignancies.
|
23406773 |
2013 |
|
Hematologic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Further research into the role of JAK2 translocations in the pathogenesis and outcomes of hematologic malignancies is warranted.
|
31063994 |
2019 |
|
Hematologic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
The rare recurrent translocation of (8;9)(p22;p24) with PCM1-JAK2 fusion was recently characterized in diverse hematological malignancies.
|
18594780 |
2008 |
|
Hematologic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We conclude that human autoantigen pericentriolar material (PCM1)-JAK2 is a novel, recurrent fusion gene in hematologic malignancies.
|
15805263 |
2005 |
|
Hematologic Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Decreased PLK4 protein expression due to promoter hypermethylation was negatively correlated with JAK2 overexpression, a common occurrence in hematological malignancies.
|
25347426 |
2015 |
|
Hematologic Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
However it is not so easy, because iPSCs from hematological malignancies have been established only from myeloproliferative neoplasms including chronic myelogenous leukemia (CML) and JAK2-V617F mutation-positive polycythemia vera (PV). iPSC technology has great potential to promote oncology research based on patient samples.
|
23807288 |
2013 |
|
Hematologic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
The critical role of Janus kinase-2 (JAK2) in regulation of myelopoiesis was established 2 decades ago, but identification of mutations in the pseudokinase domain of JAK2 in myeloproliferative neoplasms (MPNs) and in other hematologic malignancies highlighted the role of JAK2 in human disease.
|
25824690 |
2015 |
|
Hematologic Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
With the discoveries of underlying mutations in JAK2, MPL, and, most recently, calreticulin (CALR), that together account for ∼90% of patients with MPNs, these conditions are now among the best characterized of hematological malignancies.
|
25696868 |
2014 |
|
Hematologic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Therefore, we have defined a potentially curative treatment for hematological malignancies expressing constitutively active JAK2.
|
24268771 |
2013 |
|
Hematologic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
JAK-2 dysregulation plays an important role as an oncogenic driver, and is thus a promising therapeutic target in hematological malignancies.
|
29262601 |
2017 |
|
Hematologic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
The diagnostic value of JAK2 mutational analysis in myeloproliferative neoplasms (MPN) is now well established and endorsed by the World Health Organization classification system for hematologic malignancies.
|
20214447 |
2010 |
|
Hematologic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
By reviewing these specific areas, we hope to have a better understanding of Jak2's role in hematologic malignancies and to shed light on the utility of Jak2 inhibitors.
|
19216843 |
2009 |
|
Hematologic Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Myeloproliferative neoplasm (MPN) is a hematologic malignancy characterized by the clonal outgrowth of hematopoietic cells with a somatically acquired mutation most commonly in JAK2 (JAK2<sup>V617F</sup>).
|
28501635 |
2017 |
|
Hematologic Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
To assess the robustness of our clinical NGS pipeline, we analyzed the results of 304 solid tumor and hematologic malignancy specimens tested simultaneously by NGS and one or more targeted single-gene tests (EGFR, KRAS, BRAF, NPM1, FLT3, and JAK2).
|
27043212 |
2016 |
|
Hematologic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Rearrangements of JAK2 are rare and have been described in various hematological neoplasms.
|
20594592 |
2010 |
|
Hematologic Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In recent years, more novel JAK2 mutations and fusion genes have been discovered in myeloproliferative neoplasms and other hematologic malignancies.
|
18538168 |
2008 |
|
Hematologic Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
JAK2 is a tyrosine kinase with oncogenic potential in hematologic malignancies.
|
21091042 |
2011 |